GlassScriptPhysician profile
David Daniel Feist
NPI 1003243437
$6,379.35
in general payments reported to CMS, 2019-2025
19 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,516 · 2022: $1,138 · 2023: $2,272 · 2024: $1,318 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110 · Consulting Fee: $1,543 · Education: $73.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.03 |
| Consulting Fee | $1,542.50 |
| Education | $73.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $2,195.81 | 2022-2024 | Vtama |
| Leo Pharma INC. | $1,420.74 | 2021-2024 | Adbry |
| Amgen INC. | $590.25 | 2021-2025 | Otezla, Otezla |
| Abbvie INC. | $541.60 | 2021-2025 | |
| Incyte Corporation | $296.71 | 2021-2023 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $252.80 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $225.43 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $154.49 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $141.64 | 2021-2023 | Tremfya |
| Sun Pharmaceutical Industries INC. | $135.38 | 2021-2022 | |
| Pfizer INC. | $125.02 | 2021-2023 | |
| Almirall LLC | $109.98 | 2021-2022 | |
| Genzyme Corporation | $45.15 | 2022 | |
| Nabriva Therapeutics, Plc | $43.03 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $36.74 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $28.12 | 2021 | |
| Galderma Laboratories, L.P. | $17.66 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $16.49 | 2021 | |
| Organon LLC | $2.31 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Feist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.